These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

444 related items for PubMed ID: 32579813

  • 1. Hydroxyurea Dose Escalation for Sickle Cell Anemia in Sub-Saharan Africa.
    John CC, Opoka RO, Latham TS, Hume HA, Nabaggala C, Kasirye P, Ndugwa CM, Lane A, Ware RE.
    N Engl J Med; 2020 Jun 25; 382(26):2524-2533. PubMed ID: 32579813
    [Abstract] [Full Text] [Related]

  • 2. Hydroxyurea for Children with Sickle Cell Anemia in Sub-Saharan Africa.
    Tshilolo L, Tomlinson G, Williams TN, Santos B, Olupot-Olupot P, Lane A, Aygun B, Stuber SE, Latham TS, McGann PT, Ware RE, REACH Investigators.
    N Engl J Med; 2019 Jan 10; 380(2):121-131. PubMed ID: 30501550
    [Abstract] [Full Text] [Related]

  • 3. Hydroxyurea dose optimisation for children with sickle cell anaemia in sub-Saharan Africa (REACH): extended follow-up of a multicentre, open-label, phase 1/2 trial.
    Aygun B, Lane A, Smart LR, Santos B, Tshilolo L, Williams TN, Olupot-Olupot P, Stuber SE, Tomlinson G, Latham T, Ware RE, REACH Investigators.
    Lancet Haematol; 2024 Jun 10; 11(6):e425-e435. PubMed ID: 38701812
    [Abstract] [Full Text] [Related]

  • 4. Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia.
    Opoka RO, Ndugwa CM, Latham TS, Lane A, Hume HA, Kasirye P, Hodges JS, Ware RE, John CC.
    Blood; 2017 Dec 14; 130(24):2585-2593. PubMed ID: 29051184
    [Abstract] [Full Text] [Related]

  • 5. Hydroxyurea with dose escalation for primary stroke risk reduction in children with sickle cell anaemia in Tanzania (SPHERE): an open-label, phase 2 trial.
    Ambrose EE, Latham TS, Songoro P, Charles M, Lane AC, Stuber SE, Makubi AN, Ware RE, Smart LR.
    Lancet Haematol; 2023 Apr 14; 10(4):e261-e271. PubMed ID: 36870358
    [Abstract] [Full Text] [Related]

  • 6. Hydroxyurea at escalated dose versus fixed low-dose hydroxyurea in adults with sickle cell disease.
    Ogu UO, Mukhopadhyay A, Patel K, Nelson MN, Strahan KS, Wu L, Smeltzer MP, Ataga KI.
    Eur J Haematol; 2024 Mar 14; 112(3):466-474. PubMed ID: 38019026
    [Abstract] [Full Text] [Related]

  • 7. Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group.
    Kinney TR, Helms RW, O'Branski EE, Ohene-Frempong K, Wang W, Daeschner C, Vichinsky E, Redding-Lallinger R, Gee B, Platt OS, Ware RE.
    Blood; 1999 Sep 01; 94(5):1550-4. PubMed ID: 10477679
    [Abstract] [Full Text] [Related]

  • 8. Reducing transfusion utilization for children with sickle cell anemia in sub-Saharan Africa with hydroxyurea: Analysis from the phase I/II REACH trial.
    Power-Hays A, Tomlinson GA, Tshilolo L, Santos B, Williams TN, Olupot-Olupot P, Smart LR, Aygun B, Lane A, Stuber SE, Latham T, Ware RE.
    Am J Hematol; 2024 Apr 01; 99(4):625-632. PubMed ID: 38332651
    [Abstract] [Full Text] [Related]

  • 9. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
    Charache S, Barton FB, Moore RD, Terrin ML, Steinberg MH, Dover GJ, Ballas SK, McMahon RP, Castro O, Orringer EP.
    Medicine (Baltimore); 1996 Nov 01; 75(6):300-26. PubMed ID: 8982148
    [Abstract] [Full Text] [Related]

  • 10. Hydroxyurea therapy in children severely affected with sickle cell disease.
    Scott JP, Hillery CA, Brown ER, Misiewicz V, Labotka RJ.
    J Pediatr; 1996 Jun 01; 128(6):820-8. PubMed ID: 8648542
    [Abstract] [Full Text] [Related]

  • 11. Hydroxyurea for sickle cell disease: a systematic review for efficacy and toxicity in children.
    Strouse JJ, Lanzkron S, Beach MC, Haywood C, Park H, Witkop C, Wilson RF, Bass EB, Segal JB.
    Pediatrics; 2008 Dec 01; 122(6):1332-42. PubMed ID: 19047254
    [Abstract] [Full Text] [Related]

  • 12. Optimizing Hydroxyurea use in children with sickle cell disease: low dose regimen is effective.
    Sharef SW, Al-Hajri M, Beshlawi I, Al-Shahrabally A, Elshinawy M, Zachariah M, Mevada ST, Bashir W, Rawas A, Taqi A, Al-Lamki Z, Wali Y.
    Eur J Haematol; 2013 Jun 01; 90(6):519-24. PubMed ID: 23489171
    [Abstract] [Full Text] [Related]

  • 13. A Phase 3 Trial of l-Glutamine in Sickle Cell Disease.
    Niihara Y, Miller ST, Kanter J, Lanzkron S, Smith WR, Hsu LL, Gordeuk VR, Viswanathan K, Sarnaik S, Osunkwo I, Guillaume E, Sadanandan S, Sieger L, Lasky JL, Panosyan EH, Blake OA, New TN, Bellevue R, Tran LT, Razon RL, Stark CW, Neumayr LD, Vichinsky EP, Investigators of the Phase 3 Trial of l-Glutamine in Sickle Cell Disease.
    N Engl J Med; 2018 Jul 19; 379(3):226-235. PubMed ID: 30021096
    [Abstract] [Full Text] [Related]

  • 14. Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease.
    Zimmerman SA, Schultz WH, Davis JS, Pickens CV, Mortier NA, Howard TA, Ware RE.
    Blood; 2004 Mar 15; 103(6):2039-45. PubMed ID: 14630791
    [Abstract] [Full Text] [Related]

  • 15. From infancy to adolescence: fifteen years of continuous treatment with hydroxyurea in sickle cell anemia.
    Hankins JS, Aygun B, Nottage K, Thornburg C, Smeltzer MP, Ware RE, Wang WC.
    Medicine (Baltimore); 2014 Dec 15; 93(28):e215. PubMed ID: 25526439
    [Abstract] [Full Text] [Related]

  • 16. Robust clinical and laboratory response to hydroxyurea using pharmacokinetically guided dosing for young children with sickle cell anemia.
    McGann PT, Niss O, Dong M, Marahatta A, Howard TA, Mizuno T, Lane A, Kalfa TA, Malik P, Quinn CT, Ware RE, Vinks AA.
    Am J Hematol; 2019 Aug 15; 94(8):871-879. PubMed ID: 31106898
    [Abstract] [Full Text] [Related]

  • 17. Low-dose hydroxycarbamide therapy may offer similar benefit as maximum tolerated dose for children and young adults with sickle cell disease in low-middle-income settings.
    Inusa BPD, Wale A, Hassan AA, Idhate T, Dogara L, Ijei I, Qin Y, Anie K, Lawson JO, Hsu L.
    F1000Res; 2018 Aug 15; 7():. PubMed ID: 30228870
    [Abstract] [Full Text] [Related]

  • 18. Effect of hydroxyurea in sickle cell anemia: a clinical trial in children and teenagers with severe sickle cell anemia and sickle cell beta-thalassemia.
    Koren A, Segal-Kupershmit D, Zalman L, Levin C, Abu Hana M, Palmor H, Luder A, Attias D.
    Pediatr Hematol Oncol; 1999 Aug 15; 16(3):221-32. PubMed ID: 10326220
    [Abstract] [Full Text] [Related]

  • 19. A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease.
    Vichinsky E, Hoppe CC, Ataga KI, Ware RE, Nduba V, El-Beshlawy A, Hassab H, Achebe MM, Alkindi S, Brown RC, Diuguid DL, Telfer P, Tsitsikas DA, Elghandour A, Gordeuk VR, Kanter J, Abboud MR, Lehrer-Graiwer J, Tonda M, Intondi A, Tong B, Howard J, HOPE Trial Investigators.
    N Engl J Med; 2019 Aug 08; 381(6):509-519. PubMed ID: 31199090
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.